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Abstract
Background: Skeletal involvement (SI) is observed at low prevalence in patients with diffuse large B-cell lymphoma
(DLBCL). Due to the rareness of this particular condition, prospective trials for these patients are scarce.
Methods: We analyzed clinical characteristics and outcome of 75 patients with DLBCL and SI in order to identify
factors with prognostic impact towards progression-free survival (PFS) and overall survival (OS).
Results: Limited stage disease (Ann Arbor stage IE-IIE) was present in 34 patients (45%), 41 patients (55%) had
advanced stage disease (Ann Arbor stage IIIE-IVE). Outcome was generally favorable for patients with DLBCL and
SI with 3-year OS of 83%. The international prognostic index (IPI) was able to distinguish between different risk
groups within this specific entity. Additionally, hypercalcemia showed to be a factor significantly associated with
inferior survival. In regard to first-line treatment modalities, consolidative radiotherapy was positively associated
with prolonged PFS and OS while intensification of chemotherapy had no significant impact.
Conclusions: In our cohort of patients with DLBCL and SI, high-risk IPI as well as presence of hypercalcemia were
associated with inferior outcome. Consolidative radiotherapy had a positive impact on survival.
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Background
Lymphoma of the bone is a rare entity which encom-
passes less than 1% of all non-Hodgkin lymphoma [1].
Its most common histologic subtype is diffuse large b-cell
lymphoma (DLBCL) [2, 3] with about 50% showing a
GCB-phenotype [4, 5]. Clinically, lymphoma of the bone
can be classified into three different forms: primary bone
lymphoma which consists of a single bone lesion but may
involve regional lymph nodes, polyostotic lymphoma
which shows multifocal skeletal lesions, and disseminated
lymphoma with secondary bone involvement [6].
In regard to prognostic influence, involvement of mul-
tiple extranodal sites in lymphoma is generally regarded a
risk factor, as reflected in the international prognostic
index (IPI) [7, 8]. However, there is few data assessing the
prognostic impact of specific extranodal sites or comparing
outcome between different extranodal sites [9, 10] and
even less on prognostic factors within a particular entity,
such as lymphoma with skeletal involvement (SI).
In DLBCL, therapy with R-CHOP (rituximab, cyclo-
phosphamide, doxorubicin, vincristine, prednisolone) is
commonly seen as standard of care [11]. Prospective
clinical trials optimizing treatment specifically for patients
with DLBCL and SI are lacking. Several retrospective
analyses see an advantage for combining chemotherapy
and radiation treatment [12–14]. Recently, a large meta-
analysis of patients with DLBCL and SI treated with
CHOP/R-CHOP showed a survival benefit for additional
radiotherapy [15]. To the authors’ knowledge there is no
published data so far regarding whether intensification of
chemotherapy might be beneficial.
In this retrospective analysis, we evaluate the clinical
course and treatment strategy of patients with newly
diagnosed DLBCL and SI presenting to the University of
Heidelberg between 2000 and 2011 with a focus set on
the identification of factors particularly relevant for the
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prognosis of this specific population as well as the im-
pact of different first-line treatment modalities.
Methods
The clinical database of the University of Heidelberg was
reviewed for patients with DLBCL treated at our institu-
tion between January 2000 and December 2011. Patients
showing SI at first diagnosis were identified and included
in this analysis. Presence of SI was determined by means
of CT scans. Data on age, sex, Ann Arbor stage, Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus, number of extranodal sites, uni- vs. multifocal SI,
serum lactate dehydrogenase (LDH), serum calcium and
serum alkaline phosphatase (AP) levels before therapy as
well as treatment modalities and outcome were obtained
by inspection of medical charts. Progression-free survival
(PFS) was defined as time from first diagnosis to the first
documentation of progressive disease or death from any
cause. Overall survival (OS) was calculated as time from
first diagnosis to death from any cause. OS and PFS
were estimated using the Kaplan Meier method. Patients
lost to follow-up were censored at the time of last
follow-up. The impact of the variables cited above on
PFS and OS was assessed by univariate regression
models after single imputation of missing values. A Cox
proportional hazards was used to model PFS and OS in
the statistical software R, version 3.0.2. Median follow-
up time was calculated using reverse Kaplan-Meier. Fur-
thermore, multivariate proportional hazards regression
models were calculated to identify prognostic factors. In
all tests, p-values < 0.05 were considered statistically sig-
nificant. This retrospective analysis was approved by the
local ethics committee of the University of Heidelberg.
Results
Clinical presentation
In total, 821 patients with DLBCL were identified of
whom 84 (10.2%) presented with SI at first diagnosis.
Nine patients were excluded for further analysis due to
prior hematologic malignancy or due to unavailability of
any data after establishment of diagnosis, resulting in a
study population of 75 patients. Median age of patients
with DLBCL and SI was 54 years (range 16–83 years).
There was a predominance of men with 51 male patients
(68%). The majority of patients (55%) were in advanced
clinical stage (Ann Arbor stage IIIE-IVE). More than
one extranodal site was present in 51 patients (68%), the
most frequent being involvement of skin / soft tissue (39
patients, 52%). Detailed clinical characteristics are given
in Table 1.
All patients received chemotherapy. The most com-
mon regimen (46 patients, 61%) was cyclophosphamide,
doxorubicin, vincristine and prednisolone (CHOP). In 27
patients (36%) a more intensive regimen than CHOP,
mainly CHOP plus etoposide or high-dose methotrexate,
was applied. Rituximab was part of systemic therapy in 60
patients (80%). Additionally to chemotherapy, 37 patients
(49%) received radiotherapy. Six patients underwent au-
tologous transplantation as part of their first-line therapy.
For details on treatment regimens refer to Table 1.
After first-line therapy, 39 patients (52%) achieved a
complete response, further 25 patients (33%) an uncon-
firmed complete response or a partial response. Stable
Table 1 Clinical characteristics and first-line treatment modalities
No. of patients (%)
n = 75 (100)
Median age [range], years 54 [16–83]
Sex
Men
Women
51 (68)
24 (32)
Ann Arbor stage
IE-IIE
IIIE-IVE
B symptoms
34 (45)
41 (55)
26 (35)
LDH
Elevated
Normal
Missing
41 (56)
32 (44)
2
ECOG
0–1
> 1
Missing
50 (72)
19 (28)
6
No. of extranodal sites
1
2
3
> 3
24 (32)
30 (40)
13 (17)
8 (11)
Calcium
Elevated
Normal
Missing
6 (9)
62 (91)
7
AP
Elevated
Normal
Missing
14 (22)
50 (78)
11
Skeletal involvement
Unifocal
Multifocal
45 (60)
30 (40)
Chemotherapy
Palliative
CHOP
more intensive than CHOP
2 (3)
46 (61)
27 (36)
Rituximab 60 (80)
Radiotherapy 37 (49)
CNS treatment 20 (27)
Autologous transplantation 6 (8)
Lehners et al. BMC Cancer  (2017) 17:128 Page 2 of 7
disease was noted in 1 (1%), primary refractory disease
in 8 patients (11%). Two patients had no formal response
evaluation. A total of 18 relapses and 15 deaths of any
cause were documented. Survival analysis showed a 3-year
PFS of 73% and a 3-year OS of 83%. The median follow-
up was 38 months.
Factors predicting outcome
To assess the prognostic value of various factors on PFS
and OS, we analyzed the individual impact of each of the
five IPI components as well as of three bone disease re-
lated factors, i.e. uni- vs. multifocal SI, presence of hyper-
calcemia, serum level of AP. Of the five IPI components,
Ann Arbor stage IIIE-IVE, age > 60 years and ECOG> 1
were significantly associated with both inferior OS and
PFS in univariate analysis, whereas elevated serum LDH
and extranodal sites > 1 did not have any significant influ-
ence. However, extranodal sites > 2 showed significant
impact towards PFS and extranodal sites > 3 was highly
significantly associated with both inferior PFS and OS
(p = 0.001 and p = 0.004, resp.). Of the three additional
bone related factors presence of hypercalcemia showed
a highly significant impact on PFS and OS (p = 0.006 and
p = 0.0007, resp.) while neither elevated AP nor multifocal
bone disease did show any influence. Details of univariate
analysis are presented in Table 2 and Fig. 1.
In multivariate analysis, number of extranodal sites > 3
was significantly associated with both inferior OS (p = 0.04)
and PFS (p = 0.01); hypercalcemia showed a negative in-
fluence on OS (p = 0.04), Ann Arbor stage IIIE-IVE on
PFS (p = 0.01). Details of multivariate analysis are pre-
sented in Table 3.
Risk scores
According to IPI risk stratification, 18 patients (24%)
were low risk (IPI 0–1), 35 (47%) intermediate risk (IPI
2–3) and 16 (21%) high risk (IPI 4–5). The outcome of
patients with low risk IPI was excellent with 3-year PFS
of 100% and OS of 100%, whereas patients with inter-
mediate or high risk IPI had a 3-year PFS of 70 and 41%
and a 3-year OS of 82 and 58%, respectively (see Fig. 2).
Risk stratification applying the IPI score was statistically
significant with p = 0.002 for PFS and p = 0.015 for OS.
We tested whether risk stratification could be improved
for the population of patients with DLBCL and SI by
utilizing the results of the single risk factor analysis. A
new adapted IPI was created including only the IPI fac-
tors that had shown significant influence on PFS and
OS and adding the highly significant bone related factor
hypercalcemia. However, while risk stratification using
this new bone score was good, internal validation testing
still showed the standard IPI to be superior.
Influence of first-line treatment modalities
In regard to first-line treatment modalities, the addition of
rituximab to chemotherapy did not improve outcome in
univariate analysis (p = 0.87 for OS, and p = 0.58 for PFS).
Similarly, escalation of chemotherapy to a more aggressive
regimen than CHOP was not significantly associated with
prolonged survival (p = 0.21 for OS, and p = 0.10 for PFS).
Consolidative radiotherapy, however, (excluding those
patients who were primary refractory to chemotherapy
or deceased before first response evaluation and there-
fore could not undergo adjuvant radiotherapy) had a
major impact on OS (p = 0.02), yet interestingly did not
Table 2 Univariate analysis of possible prognostic factors and impact of first-line treatment modalities on PFS and OS
PFS OS
HR [95% CI] P HR [95% CI] P
Age >60 years 2.85 [1.19, 6.86] 0.02 3.70 [1.22, 11.22] 0.02
Ann Arbor stage IIIE-IVE 4.92 [1.67, 14.52] 0.004 6.41 [1.43, 28.59] 0.01
LDH above normal 2.18 [0.89, 5.33] 0.09 2.29 [0.72, 7.26] 0.16
ECOG >1 3.34 [1.45, 7.70] 0.005 4.27 [1.54, 11.83] 0.005
No. of extranodal sites
> 1
> 2
> 3
1.24 [0.50, 3.05]
2.64 [1.09, 6.36]
5.69 [1.99, 16.31]
0.64
0.03
0.001
1.11 [0.38, 3.27]
2.56 [0.87, 7.51]
5.91 [1.79, 19.53]
0.85
0.09
0.004
hypercalcemia 4.69 [1.57, 14.03] 0.006 7.52 [2.34, 24.12] 0.0007
AP above normal 0.88 [0.35, 2.16] 0.77 0.71 [0.22, 2.24] 0.56
Multifocal bone lesions 1.10 [0.48, 2.52] 0.83 1.23 [0.44, 3.46] 0.69
Rituximab 0.76 [0.29, 2.00] 0.58 1.12 [0.30, 4.14] 0.87
Intensified chemotherapy 0.44 [0.16, 1.18] 0.10 0.44 [0.12, 1.57] 0.21
Radiotherapy 0.55 [0.20, 1.47] 0.23 0.09 [0.01, 0.72] 0.02
Abbreviations: HR indicates hazard ratio, CI confidence interval, and P p-value
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significantly impact PFS (p = 0.23). For details on uni-
variate analysis see Table 2 and Fig. 3.
In multivariate analysis, a positive association was
seen between additional rituximab and prolonged PFS
(p = 0.008), yet not OS. Intensified chemotherapy did
not significantly improve outcome. However, consolida-
tive radiotherapy had a major impact on both improved
PFS (p = 0.0006) and OS (p = 0.002).
Discussion
In this retrospective analysis of patients with newly diag-
nosed DLBCL with SI, we found an overall favorable
outcome with a 3-year OS of 83% and 3-year PFS of
73%. However, patients with Ann Arbor stage IIIE-IVE,
hypercalcemia, or no. of extranodal sites > 3 had a sig-
nificantly inferior survival. Evaluation of the impact of
first-line treatment modalities revealed that while con-
solidative radiotherapy had a positive influence towards
prolonged OS, intensification of chemotherapy had no
significant impact on survival. However, this analysis
was not powered to detect a benefit of intensification
of chemotherapy on survival.
Analysis of prognostic factors has led to the develop-
ment of the IPI [7] for patients with malignant lymphoma
with its validity having been confirmed in the rituximab
era [8]. For certain sub-entities, however, such as follicular
Fig. 1 Kaplan-Meier curves for OS (a-c) and PFS (d-f) stratified by Ann Arbor stage IIIE/IVE (a, d), no. of extranodal sites > 3 (b, e), and hypercalcemia
(c, f). Patients with DLBCL and SI are presented stratified by the three risk factors which showed a significant impact in univariate and multivariate
analysis, namely Ann Arbor stage IIIE/IVE, no. of extranodal sites > 3, and hypercalcemia (from left to right)
Table 3 Multivariate analysis of possible prognostic factors and impact of first-line treatment modalities on PFS and OS
PFS OS
HR [95% CI] P HR [95% CI] P
Age >60 years 2.40 [0.90, 6.38] 0.08 1.75 [0.37, 8.24] 0.48
Ann Arbor stage IIIE-IVE 5.65 [1.47, 21.80] 0.01 9.55 [0.87, 104.27] 0.06
LDH above normal 2.16 [0.72, 6.48] 0.17 3.60 [0.56, 23.12] 0.18
ECOG >1 2.80 [0.93, 8.48] 0.07 3.93 [0.78, 20.02] 0.10
No. of extranodal sites >3 5.34 [1.40, 20.32] 0.01 6.81 [1.09, 42.72] 0.04
hypercalcemia 1.76 [0.36, 8.54] 0.48 6.92 [1.09, 44.01] 0.04
AP above normal 0.93 [0.29, 2.97] 0.90 0.67 [0.13, 3.38] 0.63
Multifocal bone lesions 0.35 [0.11, 1.11] 0.08 0.39 [0.08, 1.81] 0.23
Rituximab 0.16 [0.04, 0.62] 0.008 0.23 [0.03, 1.80] 0.16
Intensified chemotherapy 0.50 [0.17, 1.49] 0.21 0.62 [0.13, 2.96] 0.55
Radiotherapy 0.13 [0.04, 0.42] 0.0006 0.01 [0.0006, 0.18] 0.002
Abbreviations: HR indicates hazard ratio, CI confidence interval, and P p-value
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and mantle cell lymphoma, specific scoring systems, i.e.
Follicular Lymphoma IPI (FLIPI [16]) and Mantle cell
lymphoma IPI (MIPI [17]), have been developed which
more accurately distinguish between different prognos-
tic groups in their respective fields. In DLBCL with SI
no specific prognostic score exists so far, therefore the
IPI is commonly used for these patients. In our cohort
of patients with newly diagnosed DLBCL with SI, the
IPI was able to separate between groups of low, inter-
mediate and high risk patients. However, looking at the
individual risk factors, of the five IPI components, only
three factors, i.e. Ann Arbor stage IIIE-IVE, age >
60 years, and ECOG > 1, had significant impact on both
PFS and OS in univariate analysis. In multivariate ana-
lysis, Ann Arbor stage IIIE-IVE was the only IPI com-
ponent with significant influence. This is consistent
with reports of the favorable outcome of limited stage
I-II DLBCL of the bone [14]. In regard to extranodal
sites, we found a higher number of extranodal sites, i.e.
> 3, to be highly predictive for both inferior PFS and
OS. The observation that not all IPI components might
be relevant for DLBCL treated with rituximab contain-
ing regimens has been made by several authors and dif-
ferent revisions of the IPI were suggested [18, 19].
Similarly, a higher cut-off for the number of extranodal
sites was positively evaluated [20]. The latter as well as
our findings might imply that not extranodal involve-
ment of every site is necessarily associated with inferior
survival. An individual assessment of specific organs in-
volved by DLBCL showed a negative prognostic impact
only for involvement of pleura, small intestine, peritoneum,
adrenal gland, testis, bone marrow and peripheral blood
while SI was not a significant adverse factor in multivariate
analysis [9].
As surrogate markers for increased bone metabolism we
evaluated the prognostic impact of hypercalcemia, ele-
vated serum AP and multifocal vs unifocal bone lesions.
While only few patients showed hypercalcemia, its pres-
ence was associated with a very poor outcome. DLBCL
presenting with SI and hypercalcemia has been reported
as a rare and very aggressive disease [21–23]. Mechanistic-
ally, production of osteoclast-activating factors by the
lymphoma or its microenvironment seems to be largely
responsible for bone destruction and hypercalcemia [24].
Presence of multifocal bone lesions was not associated
with inferior survival in our study population. This is con-
sistent with a recent retrospective analysis of multifocal
bone DLBCL showing an overall favorable prognosis of
this particular entity [25].
In our cohort of patients with DLBCL and SI, the IPI
was able to distinguish between different risk groups.
However, our risk factor analysis found a different set of
Fig. 2 Kaplan-Meier curves for OS (a) and PFS (b) applying the IPI score. Patients with IPI score <2 are categorized as ‘low’, with IPI score 2 or 3 as
‘intermediate’ and ‘high’ if the IPI is higher than 3
Fig. 3 Kaplan-Meier curves for OS (a) and PFS (b) stratified by radiotherapy
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variables to have significant impact on survival. These
results suggest that for this particular disease entity an
improved and more specifically applicable risk score
might be achieved. Yet, in our small patient cohort, no
newly adapted score could be shown to be superior to the
standard IPI in internal validation. Therefore, the develop-
ment of a specific prognostic score for patients with
DLBCL and SI should be attempted in future studies on
larger populations.
Analysis of first-line treatment modalities in our patient
cohort did not show any difference between patients
treated with or without additional rituximab in univariate
analysis. However, in multivariate analysis, rituximab
seemed to be beneficial in regard to PFS, yet not OS.
These slightly conflicting observations might be con-
founded by the fact that the number of patients in our
cohort not receiving rituximab was very small (n = 15)
compared to those treated with a rituximab containing
regimen (n = 60) and that they had received treatment
predominantly during the earlier years of the time
period covered in our study. Therefore, it may not be
possible to make reliable conclusions as to the signifi-
cance of rituximab in the treatment of DLBCL patients
with SI in this study. The impact of rituximab on sur-
vival of patients with extranodal DLBCL has been con-
troversially discussed with some studies seeing a benefit
[3, 26] for the implementation of immuno-chemotherapy
while others do not see any such effect [15, 27]. Why
rituximab might fail to improve survival of patients with
DLBCL and SI has not been satisfactorily explained so far.
Thus, there is clearly not sufficient data at this moment to
justify withholding this potentially effective treatment op-
tion from patients with DLBCL and SI.
Additionally, we analyzed whether escalation of CHOP
to a more aggressive regimen was beneficial. Neither in
univariate nor in multivariate analysis a significant effect
could be seen for this strategy. Consolidative radiotherapy
has been positively evaluated in patients with DLBCL [28].
Recently, a large meta-analysis confirmed an event-free
survival benefit for patients with DLBCL with SI treated
with chemotherapy followed by radiation [15]. In our
analysis, consolidative radiotherapy was significantly as-
sociated with both prolonged PFS and OS. Therefore,
additional radiotherapy after a CHOP-like chemother-
apy seems to be recommendable. It is worth mention-
ing, however, that patients with DLBCL and SI with a
low-risk IPI showed an excellent outcome irrespective
of the treatment regimen they received.
As a retrospective study this analysis has a number of
limitations. The major drawback may be the relatively
small number of patients limiting statistical power. This is
in part due to the rareness of this particular lymphoma as
well as to the fact that this is a single center experience.
Furthermore, therapy was not homogenous in the entire
study population, as a large time period was covered and
treatment options were chosen mostly at the physician’s
discretion. To address these difficulties, larger multicenter
studies on prognostic factors and therapeutic strategies in
this lymphoma entity would be desirable.
Conclusions
In conclusion, we could show that while patients with
DLBCL and SI show a generally favorable outcome, Ann
Arbor stage IIIE/IVE, no. of extranodal sites > 3 and hyper-
calcemia were significantly associated with inferior survival
in this cohort. Regarding first-line treatment modalities,
escalation of CHOP-like chemotherapy to a more aggres-
sive regimen had no impact on survival while consolidative
radiotherapy was associated with prolonged PFS and OS.
The latter might be especially relevant for patients in
advanced stage or with aggressive disease, e.g. presenting
with hypercalcemia. Therefore, exact assessment of the in-
dividual prognosis of patients even within rare lymphoma
entities is essential in order to allow for individualized
therapy.
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